Abstract
SARS-CoV-2 causes a severe inflammatory syndrome (COVID-19) leading, in many cases, to bilateral pneumonia, severe dyspnea and in ∼5% of these, death. DNA methylation is known to play an important role in the regulation of the immune processes behind COVID-19 progression, however it has not been studied in depth, yet. In this study, we aim to evaluate the implication of DNA methylation in COVID-19 progression by means of a genome-wide DNA methylation analysis combined with DNA genotyping.
The results reveal the existence of epigenomic regulation of functional pathways associated with COVID-19 progression and mediated by genetic loci. We found an environmental trait-related signature that discriminates mild from severe cases, and regulates IL-6 expression via the transcription factor CEBP. The analyses suggest that an interaction between environmental contribution, genetics and epigenetics might be playing a role in triggering the cytokine storm described in the most severe cases.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work has been supported through Consejería de Transformación Económica, Industria, Conocimiento y Universidades of the regional government of Andalucía cofounded by the European Union through European Regional Development Fund (FEDER, CV20-10150), Consejo Superior de Investigaciones científicas (CSIC-COV19-016/202020E155) and Junta de Castilla y León (Proyectos COVID 07.04.467B04.74011.0 and IBGM excellence programme CLU-2029-02). G.B. is supported by the Instituto de Salud Carlos III (ISCIII, Spanish Health Ministry) through the Sara Borrell subprogram (CD18/00153).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The regional ethical committees from Andalucía (Comité Coordinador de Ética de la Investigación Biomédica de AndalucÁa) and from Valladolid (COMITÉ DE ÉTICA DE LA INVESTIGACIÓN CON MEDICAMENTOS ÁREA DE SALUD VALLADOLID) approved the protocols and gave their ethical approval for this study and all recruited individuals signed the informed consent prior to recruitment.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Genotypes summary statistics can be accessed through COVID-19 Host Genetic Initiative web page (https://www.covid19hg.org/), included in project Determining the Molecular Pathways and Genetic Predisposition of the Acute Inflammatory Process Caused by SARS-CoV-2 (SPGRX). Methylation profiling will be available from Gene Expression Omnibus (GEO) upon manuscript publication.
